ReviewOphthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)2026
Presbyopia: Current Perspectives and Prospects for Patients.
Review in Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presbyopia, the ubiquitous loss of near vision function with age, has undergone significant reframing over the past decade. Indeed, in the last 10 years since Ophthalmic & Physiological Optics' last feature issue on presbyopia, research has progressed from viewing the refractive condition primarily as a decline in accommodative amplitude to recognising it as a multifactorial physiological process involving progressive lenticular stiffening, alterations in the capsule and zonule nexus and changes in optics. Advances in imaging and biomechanical assessment have deepened our understanding of the ageing crystalline lens and ciliary apparatus, while providing candidates for future clinical translation. Concurrent developments in correction and treatment have broadened the potential therapeutic landscape. Non-surgical approaches, particularly the emergence of pharmacological options including topical miotics and early-stage lens-softening agents, have marked the first major shift in presbyopia management in decades. Ongoing innovations in spectacle and contact lens designs have refined extended depth of focus and multifocal optics, while surgical strategies have continued to evolve. Despite these advances, consistent challenges remain in balancing near visual performance with quality of vision and in translating innovative laboratory and engineering innovations into stable, real-world patient benefits. In parallel, there has been a growing emphasis on patient-centred outcomes, reflecting an increased appreciation of the variability in visual demands, expectations and tolerance for compromises among presbyopic patients. Consequently, this narrative review synthesises some of the key developments related to presbyopia over the last 10 years, outlining future opportunities for restorative and personalised presbyopia care.
Indexed as
Identifiers
42018249What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.